Overall rank by patents
#29,357
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Mayne Pharma International PTY. Ltd
USPTO PatentsView assignee record - 9 granted patents across 2 technology areas, active 2016–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
9
Total patents granted
2
CPC technology areas
26.4
Avg claims per patent
-50%
5-year filing velocity
The verdict
Mayne holds 9 US patents across 2 technology areas, rank #29,357 of 50,000 tracked assignees.
- #29,357
- of 50,000 US assignees by volume
- Top 67%
- by Innovation Score (30.2/100)
- 26.4
- avg claims per patent
- -50%
- filing velocity, last 5 yrs
Portfolio overview
Mayne Pharma International PTY. Ltd has been granted 9 US utility patents between 2016 and 2023, placing Mayne Pharma International PTY. Ltd at rank #29,357 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 26.4 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Mayne Pharma International PTY. Ltd is one of the more focused assignees in the PatentsView dataset. By volume, Mayne sits between Maxamcorp Holding, S.l. (9 patents, rank #29,353) and MD Health RX Solutions, Llc (9 patents, rank #29,361) - the closest US assignees by grant volume. The composite Innovation Score of 30.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 6 in the 2015–2019 window, a -50% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Mayne Pharma International PTY. Ltd's 26.4 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Mayne Pharma International PTY. Ltd against peers pursuing similar technology classes.
Who files at Mayne's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Maxamcorp Holding…
MAXAMCORP HOLDING, S.L.
9 patents
- Maxpoint Interact…
MAXPOINT INTERACTIVE, INC.
9 patents
- Maxxmar
MAXXMAR INC
9 patents
- Maxzone Vehicle L…
MAXZONE VEHICLE LIGHTING CORP.
9 patents
- MBA B V
MBA B.V.
9 patents
- Mclear &
MCLEAR & CO.
9 patents
- MCOR
MCOR TECHNOLOGIES LIMITED
9 patents
- MD Health RX Solu…
MD Health RX Solutions, LLC
9 patents
- Mayne Pharma Inte… ◀
MAYNE PHARMA INTERNATIONAL PTY. LTD
9 patents
What this shows Mayne holds 9 patents at rank #29,357, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Mayne
By rank, the assignees closest to #29,357 in granted patent volume.
- Maxamcorp Holding, S.l. #29,353 · 9 patents
- Maxpoint Interactive, Inc. #29,354 · 9 patents
- Maxxmar Inc #29,355 · 9 patents
- Maxzone Vehicle Lighting Corp. #29,356 · 9 patents
- MBA B.v. #29,358 · 9 patents
- Mclear & Co. #29,359 · 9 patents
- MCOR Technologies Limited #29,360 · 9 patents
- MD Health RX Solutions, Llc #29,361 · 9 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Mayne's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
Mayne's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
30 Top 67% higher than 33% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 4 | 44.4% |
| 2017 | 1 | 11.1% |
| 2019 | 1 | 11.1% |
| 2020 | 2 | 22.2% |
| 2023 | 1 | 11.1% |
Which technologies does Mayne Pharma International PTY. Ltd patent most?
Top 2 of 2 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Velocity Declining
Frequently Asked Questions
How many patents does Mayne Pharma International PTY. Ltd hold?
Mayne Pharma International PTY. Ltd holds 9 US granted patents filed between 2016 and 2023, spanning 2 technology areas.
What is Mayne Pharma International PTY. Ltd's Innovation Score?
Mayne Pharma International PTY. Ltd has an Innovation Score of 30.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Mayne Pharma International PTY. Ltd focus on?
Mayne Pharma International PTY. Ltd's top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 9 patents. The company has filed patents in 2 CPC subclasses total.
Is Mayne Pharma International PTY. Ltd's patent filing rate increasing or decreasing?
Mayne Pharma International PTY. Ltd's recent filing velocity is -50% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Mayne Pharma International PTY. Ltd's patents?
Mayne Pharma International PTY. Ltd's patents average 26.4 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Mayne Pharma International PTY. Ltd patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Mayne's 9 grants land it in the top 67% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Mayne ranks #29,357 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.